PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

The anti-PD-1/PD-L1 therapy has been demonstrated effective and safe for advanced NSCLC patients, especially for EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors) resistant NSCLC (non-small cell lung cancer) patients with EGFR mutations. However, whether the anti-PD-1/PD-L1 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Xiang, Cheng, Wang, Yuling, Duan, Yuanyuan, Liu, Ci, Zhang, Yajing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731894/
https://www.ncbi.nlm.nih.gov/pubmed/29254184
http://dx.doi.org/10.18632/oncotarget.21328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731894/
https://www.ncbi.nlm.nih.gov/pubmed/29254184
http://dx.doi.org/10.18632/oncotarget.21328

Ejemplares similares